Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Abdominal Wall
25%
Abdominal Wall Hernia
16%
Angiogenesis
17%
Angiosarcoma
25%
Bariatric Surgery
47%
Body Mass Index
51%
Cancer
26%
Chemotherapy
23%
Cholecystectomy
17%
Connective Tissue Cancer
50%
Crohn's Disease
26%
Cytoreductive Surgery
27%
Digestive System Surgery
19%
Disease Free Survival
19%
Disease Specific Survival
16%
Diseases
73%
Elderly Patient
31%
Gastrectomy
20%
Gastric Bypass
80%
Gastric Bypass Surgery
80%
Histology
21%
Hyperthermic Intraperitoneal Chemotherapy
32%
Intraperitoneal Chemotherapy
31%
Laparoscopic Sleeve Gastrectomy
25%
Liposarcoma
33%
Long-Term Outcome
47%
Lymph Node
39%
Lymph Node Metastasis
34%
Malignant Neoplasm
16%
Metastatic Carcinoma
24%
Morbidity
59%
Neoplasm
66%
Obesity Medicine
24%
Overall Survival
68%
Pancreas Adenocarcinoma
32%
Pancreas Cancer
29%
Pancreas Islet Cell Tumor
18%
Peritoneum Metastasis
31%
Postoperative Complication
41%
Recurrent Disease
90%
Reoperation
21%
Retroperitoneal Sarcoma
81%
Roux-en-Y Gastric Bypass
18%
Sleeve Gastrectomy
70%
Soft Tissue Sarcoma
64%
Surgeon
20%
Surgical Anastomosis
88%
Surgical Oncology
21%
Tissue Microarray
29%
Tumor
51%
Keyphrases
Abdominal Wall Reconstruction
19%
Angiosarcoma
19%
Bariatric
27%
Bariatric Surgery
52%
Body Mass Index
37%
Borderline Resectable Pancreatic Cancer
19%
Chemotherapy
28%
Crohn's Disease
32%
Cytoreductive Surgery
27%
Dedifferentiated
17%
Disease-specific Survival
19%
Elderly Patients
31%
First Recurrence
18%
FOLFIRINOX
18%
Gastric Bypass
19%
Human Soft Tissue
17%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
49%
Intraductal Papillary mucinous Neoplasm
25%
Laparoscopic Sleeve Gastrectomy
31%
Local Recurrence
27%
Lymph Node Metastasis
36%
Lymph Node Ratio
22%
Metabolic Surgery
41%
Multivariable
21%
Neoadjuvant
18%
One-anastomosis Gastric Bypass
60%
Overall Survival
54%
Pancreatic Ductal Adenocarcinoma
30%
Pancreaticoduodenectomy
21%
Patient Outcomes
30%
Peritoneal Metastasis
37%
Postoperative Complications
35%
Postoperative Morbidity
25%
Postoperative Outcomes
35%
Prognosticator
19%
Resection
53%
Retroperitoneal Liposarcoma
25%
Retroperitoneal Sarcoma
100%
Retrospective Analysis
29%
Roux-en-Y Gastric Bypass
19%
Sarcoma
36%
Sarcoma Cells
28%
Sleeve Gastrectomy
75%
Soft Tissue Sarcoma
90%
Surgical Oncology
22%
Tertiary Care Centers
27%
Tissue Microarray
27%
Total Weight Loss
19%
Tumor
60%
Well-differentiated
18%